Volitionrx Ltd (VNRX) - Total Assets
Based on the latest financial reports, Volitionrx Ltd (VNRX) holds total assets worth $6.90 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Volitionrx Ltd shareholders equity for net asset value and shareholders' equity analysis.
Volitionrx Ltd - Total Assets Trend (2004–2025)
This chart illustrates how Volitionrx Ltd's total assets have evolved over time, based on quarterly financial data.
Volitionrx Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Volitionrx Ltd's total assets of $6.90 Million consist of 29.9% current assets and 70.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 16.2% |
| Accounts Receivable | $317.81K | 4.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $316.70K | 4.6% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2004–2025)
This chart illustrates how Volitionrx Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see VNRX market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Volitionrx Ltd's current assets represent 29.9% of total assets in 2025, a decrease from 100.0% in 2004.
- Cash Position: Cash and equivalents constituted 16.2% of total assets in 2025, down from 100.0% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2004.
- Asset Diversification: The largest asset category is accounts receivable at 4.6% of total assets.
Volitionrx Ltd Competitors by Total Assets
Key competitors of Volitionrx Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GN Store Nord
CO:GN
|
Denmark | Dkr29.23 Billion |
|
Novocure Ltd
NASDAQ:NVCR
|
USA | $1.36 Billion |
|
Sino Medical Sciences Technology In
SHG:688108
|
China | CN¥1.34 Billion |
|
HOB Biotech Group Corp Ltd
SHG:688656
|
China | CN¥965.27 Million |
|
Zhejiang Orient Gene Biotech Co Ltd
SHG:688298
|
China | CN¥7.51 Billion |
|
Dirui Industrial Co Ltd
SHE:300396
|
China | CN¥2.62 Billion |
|
EBR Systems Inc
AU:EBR
|
Australia | AU$97.29 Million |
|
T&R Biofab Co. Ltd
KQ:246710
|
Korea | ₩83.86 Billion |
Volitionrx Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.17 | 0.52 | 5.78 |
| Quick Ratio | 0.17 | 0.52 | 5.60 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-10.17 Million | $-3.73 Million | $28.67 Million |
Volitionrx Ltd - Advanced Valuation Insights
This section examines the relationship between Volitionrx Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 38.44 |
| Latest Market Cap to Assets Ratio | 2.64 |
| Asset Growth Rate (YoY) | -26.6% |
| Total Assets | $6.90 Million |
| Market Capitalization | $18.20 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Volitionrx Ltd's assets at a significant premium (2.64x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Volitionrx Ltd's assets decreased by 26.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Volitionrx Ltd (2004–2025)
The table below shows the annual total assets of Volitionrx Ltd from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $6.90 Million | -26.58% |
| 2024-12-31 | $9.40 Million | -66.37% |
| 2023-12-31 | $27.95 Million | +52.78% |
| 2022-12-31 | $18.30 Million | -33.45% |
| 2021-12-31 | $27.49 Million | +5.12% |
| 2020-12-31 | $26.15 Million | +22.82% |
| 2019-12-31 | $21.29 Million | +21.74% |
| 2018-12-31 | $17.49 Million | +19.59% |
| 2017-12-31 | $14.62 Million | -40.87% |
| 2016-12-31 | $24.73 Million | +220.71% |
| 2015-12-31 | $7.71 Million | +124.64% |
| 2014-12-31 | $3.43 Million | +65.79% |
| 2013-12-31 | $2.07 Million | -6.59% |
| 2012-12-31 | $2.22 Million | -1.27% |
| 2011-12-31 | $2.25 Million | +462838.97% |
| 2010-12-31 | $485.00 | -85.91% |
| 2009-12-31 | $3.44K | +3.71% |
| 2008-12-31 | $3.32K | -23.51% |
| 2007-12-31 | $4.34K | +92.20% |
| 2006-12-31 | $2.26K | +2091.26% |
| 2005-12-31 | $103.00 | +51.47% |
| 2004-12-31 | $68.00 | -- |
About Volitionrx Ltd
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleos… Read more